Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totaling 253,084 shares, a growth of 210.7% from the August 31st total of 81,457 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 314,739 shares, the short-interest ratio is currently 0.8 days.
Obsidian Therapeutics Price Performance
NASDAQ OBX traded down $0.55 on Friday, reaching $12.86. 454,476 shares of the company were exchanged, compared to its average volume of 641,407. Obsidian Therapeutics has a fifty-two week low of $12.16 and a fifty-two week high of $49.97.
Wall Street Analyst Weigh In
OBX has been the topic of a number of research reports. Wall Street Zen raised shares of Obsidian Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Lifesci Capital initiated coverage on Obsidian Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 target price on the stock. Weiss Ratings began coverage on Obsidian Therapeutics in a research note on Wednesday, September 2nd. They issued a “sell (d-)” rating on the stock. Piper Sandler began coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.
About Obsidian Therapeutics
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than Obsidian Therapeutics
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
